Abstract: The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy more desirable dosing schedules.

Abstract: The present invention provides compositions comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-(d)Val-(d)Leu-(d)Val-(d)Gln-(d)Pro-Gly (SEQ ID NO: 6) to promote tight junction integrity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier. The present invention further provides methods of using the larazotide derivative compositions for promoting tight junction integrity in patients in need thereof.

Abstract: The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.

Abstract: The invention, in various aspects and embodiments, provides compositions and methods for treating or preventing inflammation of the lower gastrointestinal tract. The compositions and methods in various embodiments relate to rectal administration of pharmaceutical compositions that comprise an agent that forms one or more 4-AAPA compounds or 5-ASA compounds by azo reduction. In various embodiments, the compositions and methods treat, reduce, or prevent inflammation of the colon and/or rectum, as well as in some embodiments, an ileo-anal pouch in a subject. Compositions for rectal administration can be formulated as emulsions, suppositories (both suspension and solid), gels, and foam and foamable pharmaceutical compositions.

Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

Abstract: The present invention provides compositions and methods for treating hyperglycemia, insulin resistance, and associated organ damage, including in some embodiments diabetes mellitus (type 1 or 2), metabolic syndrome, obesity, fatty liver diseases, or kidney disease. In various embodiments, the invention involves administering a regimen of larazotide (or a derivative of larazotide) to a subject. In various embodiments, the regimen reduces dysfunction of the gastrointestinal epithelial barrier, thereby improving glycemic control. In various embodiments, the regimen of larazotide improves the effectiveness of conventional pharmaceutical interventions for hyperglycemia or diabetes mellitus.

Abstract: The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy more desirable dosing schedules.

Abstract: A system comprising a facsimile device configured to transmit a code-associated information material, an interactive user device, and a processor. Typically, the code-associated information material is a medical record to which a barcoded fax cover sheet is appended. The interactive device is preferably a computer terminal, wherein the processor is coupled to the interactive user device via the Internet. The processor is configured to receive from the facsimile device a transmission of the information material, and to display it to an authorized user upon a request from the authorized user. The information material may be displayed via Internet, or else may be faxed to an authorized user in response to a telephone call.

Abstract: A system comprising a facsimile device configured to transmit a code-associated information material, an interactive user device, and a processor. Typically, the code-associated information material is a medical record to which a barcoded fax cover sheet is appended. The interactive device is preferably a computer terminal, wherein the processor is coupled to the interactive user device via the Internet. The processor is configured to receive from the facsimile device a transmission of the information material, and to display it to an authorized user upon a request from the authorized user. The information material may be displayed via Internet, or else may be faxed to an authorized user in response to a telephone call.